Clinical Trial Update: Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and efficacy of a 0.05% topical tacrolimus formulation for ocular graft-versus-host disease; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Graft-versus-host Disease

Drugs mentioned

• Topical tacrolimus 0.05% (tacrolimus)

Snippet

Sponsor: Massachusetts Eye and Ear Infirmary | Conditions: Ocular GVHD | Phase 1 | Status: COMPLETED | Results posted: 2017-05-15